BrainCells

The company’s lead clinical program is based on the principal of blocking or antagonizing select metabotropic glutamate receptors (mGluR), which are associated with a number of CNS diseases. The company’s lead compound, BCI-632 and its prodrug, BCI-838, have been extensively studied in preclinical models for major depressive disorder, treatment resistant depression and potentially Alzheimer’s disease. BCI completed a Phase 1 study for BCI-838 and plans to initiate a proof of concept trial for treatment resistant depression.

BrainCells represents a novel approach to the way CNS drugs are discovered.

BrainCells

San Diego, CA

02.29.2012
BrainCells Inc. Announces the Successful Completion of the Single…

Read More

02.29.2012
BrainCells Inc. Announces the Successful Completion of the Single…

Read More